Article Text

Download PDFPDF

Acute-on-chronic liver failure: an update
  1. Ruben Hernaez1,
  2. Elsa Solà2,3,4,
  3. Richard Moreau5,6,7,8,9,
  4. Pere Ginès2,3,4
  1. 1Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
  2. 2Liver Unit, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
  3. 3Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  4. 4Centro d'Investigaciones Biomedicas en Red, enfermedades Hepaticas y Digestivas (CIBEReHD), Barcelona, Spain
  5. 5Inserm, U1149, Centre de Recerche sur l'inflammation (CRI), Paris, France
  6. 6Faculté de Médicine, Université Paris Diderot, Paris, France
  7. 7Départment Hospitalo-Universitaire (DHU) UNITY, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
  8. 8Laboratoire d'Excellence (Labex) Inflamex, CUE Sorbonne Paris Cité, Paris, France
  9. 9European Foundation for the Study of Chronic Liver Failure (EF-CLIF), Barcelona, Spain
  1. Correspondence to Dr Pere Ginès, Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona 08036, Spain; PGINES{at}clinic.cat; pgines{at}clinic.ub.es

Footnotes

  • RM and PG are joint senior authors.

  • Contributors RH, PG, ES and RM wrote and contributed to this paper equally. Final review and approval was given by all authors.

  • Funding Some of the work mentioned has been supported by grants awarded to PG (PI12/00330), integrated in the Plan Nacional I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and European Regional Development Fund FEDER; Agencia de Gestió d'Ajuts Universitaris I de Recerca (AGAUR) 2014/SGR 708; PG is a recipient of an ICREA Academia Award. Acknowledgement is made to the LiverHope project, part of the EC H2020-SC1-2016-RTD programme, number: 731875.

  • Competing interests PG declares that he has received research funding from Ferring Pharmaceuticals, Grifols S.A. and Sequana Medical. He has participated on Advisory Boards for Ferring Pharmaceuticals, Promethera and Novartis.

  • Provenance and peer review Commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • RM and PG are joint senior authors.

  • Contributors RH, PG, ES and RM wrote and contributed to this paper equally. Final review and approval was given by all authors.

  • Funding Some of the work mentioned has been supported by grants awarded to PG (PI12/00330), integrated in the Plan Nacional I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and European Regional Development Fund FEDER; Agencia de Gestió d'Ajuts Universitaris I de Recerca (AGAUR) 2014/SGR 708; PG is a recipient of an ICREA Academia Award. Acknowledgement is made to the LiverHope project, part of the EC H2020-SC1-2016-RTD programme, number: 731875.

  • Competing interests PG declares that he has received research funding from Ferring Pharmaceuticals, Grifols S.A. and Sequana Medical. He has participated on Advisory Boards for Ferring Pharmaceuticals, Promethera and Novartis.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.